Evidence map›Paper›PMID 24722878›Full record

Trial reportLab on a chip2014

Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes.

Shailender Singh Kanwar, Christopher James Dunlay, Diane M Simeone, Sunitha Nagrath

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lab on a chip, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 300 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
300citing papers in PubMed, 1 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

300 citing papers in PubMed, 1 synthesis or guideline pooled it, 645 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

240 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Shailender Singh KanwarDepartment of Chemical Engineering, College of Engineering University of Michigan, 2300 Hayward Street, Ann Arbor, Michigan-48109, USA. snagrath@umich.edu.
Christopher James Dunlay
Diane M Simeone
Sunitha Nagrath
Ann Arbor Center for Independent Living · USMichigan Center for Translational Pathology · USUniversity of Michigan–Ann Arbor · US

Funding

Translational Research in GI CancerP50CA130810 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENNER, DEAN E. · 2010 to 2016
$11.8M
Engineering sensitive microfluidic multiplex technology for isolating circulatingDP2OD006672 · OD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NAGRATH, SUNITHA · 2009 to 2009
$2.1M
NCI NIH HHS CA130810NCI NIH HHS P50 CA130810NIH HHS 1DP2OD006672-01NIH HHS DP2 OD006672
6 · The paper itself

Abstract

Membrane bound vesicles, including microvesicles and exosomes, are secreted by both normal and cancerous cells into the extracellular space and in blood circulation. These circulating extracellular vesicles (cirEVs) and exosomes in particular are recognized as a potential source of disease biomarkers. However, to exploit the use of circulatory exosomes as a biomarker, a rapid, high-throughput and reproducible method is required for their isolation and molecular analysis. We have developed a simple, low cost microfluidic-based platform to isolate cirEVs enriched in exosomes directly from blood serum allowing simultaneous capture and quantification of exosomes in a single device. To capture specific exosomes, we employed "ExoChip", a microfluidic device fabricated in polydimethylsiloxane (PDMS) and functionalized with antibodies against CD63, an antigen commonly overexpressed in exosomes. Subsequent staining with a fluorescent carbocyanine dye (DiO) that specifically labels the exosomes, we quantitated exosomes using a standard plate-reader. Ten independent ExoChip experiments performed using serum obtained from five pancreatic cancer patients and five healthy individuals revealed a statistically significant increase (2.34 ± 0.31 fold, p < 0.001) in exosomes captured in cancer patients when compared to healthy individuals. Exosomal origins of ExoChip immobilized vesicles were further confirmed using immuno-electron-microscopy and Western blotting. In addition, we demonstrate the ability of ExoChip to recover exosomes with intact RNA enabling profiling of exosomal-microRNAs through openarray analysis, which has potential applications in biomarker discovery. Based on our findings, ExoChip is a well suited platform to be used as an exosome-based diagnostic and research tool for molecular screening of human cancers.

Indexed as

Cell-Derived MicroparticlesExosomesLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesHumansMaleMicroRNAsPancreatic NeoplasmsRNA, NeoplasmMicroRNAsRNA, Neoplasm

Identifiers

PMID24722878
PMCPMC4134440
OpenAlexW2022805251

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.